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Abstract
Hyaluronan (HA) is a component that is particularly abundant in the synovial fluid. Randomized, double-blinded,
placebo-controlled trials carried out between 2008 and 2015 have proven the effectiveness of HA for the treatment
of symptoms associated with synovitis, and particularly, knee pain, relief of synovial effusion or inflammation, and
improvement of muscular knee strength. The mechanism by which HA exerts its effects in the living body,
specifically receptor binding in the intestinal epithelia, has gradually been clarified. This review examines the effects
of HA upon knee pain as assessed in clinical trials, as well as the mechanism of these effects and the safety of HA.
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Introduction
The number of patients with osteoarthritis (OA) is in-
creasing in developed countries. In the US, 43 million
patients were estimated to have OA in 1997, and this
figure is projected to grow to more than 60 million by
2020 [1].
Severe OA is treated by osteotomy or artificial joint re-
placement, whereas conservative treatments include
intra-articular injection of hyaluronan (HA) [2]. The in-
jections improve symptoms, although they represent a
mental burden and the risk of infection for patients who
need to visit the hospital regularly to receive these pain-
ful injections.
Meanwhile, dietary supplements such us HA, glucosa-
mine, and chondroitin are sold as health foods, largely
targeting problems with the knee. The effects of low-
dose HA treatment for knee pain has been the source of
much research (for example, a dose of HA not more
than 240 mg/day; Table 1) compared with glucosamine
(1500 mg/day) and chondroitin (675 mg/day) [3]. HA
dietary supplements impose a small burden on patients.
The average wholesale price for five vials of intra-
articular HA injection (Hyalgen®, Fidia Farmaceutici
S.p.A., Italy) is 661 USD, which is effective for 6 months
[4]. This equals to 110 USD per month. In contrast, the
cost of effective HA dietary supplements for one month
is 50 USD (Play Again Now®, Viscos LLC., USA). There
have been no reports regarding the cost-effectiveness of
intra-articular injection versus dietary supplements.
However, there are some advantages for consumers with
regard to HA dietary supplements, when one considers
the potential risks and benefits.
In 2004, Bucci and Turpin reported a review article on
the effectiveness of dietary supplements containing HA
in the US; however, the report does not mention ran-
domized, double-blind, placebo-controlled trials [5].
Therefore, this review discusses the efficacy of ingested
HA in treating knee pain based on data from random-
ized, double-blind, placebo-controlled trials as well as
the mechanism of action and safety of dietary HA.
Characteristics of HA
HA is a high molecular-weight polysaccharide composed
of repeating polymeric disaccharides of D-glucuronic acid
and N-acetyl-D-glucosamine (Fig. 1) [6]. All vertebrates
and few microorganisms synthesize HA in vivo. In human
beings, HA is present in every connective tissue and organ
such as skin, synovial fluid, blood vessels, serum, brain,
cartilage, heart valves, and the umbilical cord [7]. In par-
ticular, synovial fluid has the highest concentration of HA
anywhere in the body at 3–4 mg/mL [8].
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Table 1 Summary of the knee pain-improving effects of ingested hyaluronan
Study designs Materials and Methods Subjects Results References
Randomized, double-blind,
placebo-controlled trial
HA mixture at 630 mg (HA 60 mg; MW
<5 k) daily for 2 weeks
24 patients with
knee pain (in Japan)





HA mixture at 80 mg (HA 48 mg; MW
1000 k) daily for 2 months
20 patients aged
≥40 years with knee
OA (in USA)
Significant improve from baseline
for bodily pain bodily pain subscale




HA at 240 mg (MW 900 k) daily for
8 weeks
26 patients aged 50
~ 65 years with knee
pain (in Japan)









pain score > 10] (in
USA)
Significant improve of tatal WOMAC




HA mixture at 80 mg (HA 48 mg; MW N/




Significant improve of synovial




HA mixture at 630 mg (HA 60 mg; MW




Significant improve of pain/step-up





HA mixture at 2520 mg (HA 72 mg; MW









HA at 200 mg (MW 900 k) daily for
12 months
38 patients with
knee OA (in Japan)




≦70 years with knee
OA (in Japan)
Significant improve of total JKOM




HA mixture at 80 mg (HA 52 mg; MW N/





Significant improve of joint
mechanics and muscle function
[42]
Meta-analysis included in two
randomized, controlled, double-
blind, placebo-controlled trials
HA mixture at 80 mg (HA 48 mg; MW N/
A) daily for 3 months
148 healthy
individuals with mild
knee pain (in Spain)
Significant improve of muscle





HA mixture at 80 mg (HA 52 mg; MW N/





Significant improve of articular pain,





HA mixture at 80 mg (HA 56 mg; MW N/
A) daily for 3 months
40 patients with
knee OA (in USA)
Significant improve of total WOMAC




HA mixture daily for 4 weeks (HA 225 mg
daily for first 2 weeks, HA 150 mg daily
for last 2 weeks; MW 2500 k ~ 2800 k)
72 patients with
knee pain (in USA)
Significant improve of knee pain [46]
Fig. 1 The structure of hyaluronan
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HA is a polysaccharide with a mean molecular
weight (MW) ranging from several hundred to several
millions, and thus, it has high viscosity in water. The
viscosity of synovial fluid is attributable to HA and
serves as a lubricant for joint movements, resulting in
a coefficient of friction of nearly zero in joint cartil-
age [9]. It is known that patients with OA have di-
minished HA concentrations in their synovial fluid
[10]. To restore the decreased levels of HA and treat
OA, HA intra-articular injections are widely used.
The functions of HA include preventing cartilage de-
naturation [11, 12], protecting the outer layer of car-
tilage [13–20], blocking synovial inflammation [21,
22], increasing chondrocyte density [23], promoting
synovium metabolism [24], normalizing synovial fluid
[25], and treating sharp pain [26]. The mechanism by
which HA diminishes pain has been reported. HA
intra-articular injections decrease the levels of inflam-
matory substances such as prostaglandin E2 resulting
in reduced pain [27, 28]. Therefore, HA is known to
have a strong relationship with knee joint health.
Mechanisms of oral HA treatment for knee pain
It is generally believed that it is difficult for the body to
absorb a polysaccharide. HA is not absorbed into the
body as a high-molecular-weight polymer after ingestion.
A test using intestinal epithelia model cells (Caco-2
cells) revealed that HA with a MW exceeding 1 × 105 is
rarely absorbed. On the contrary, the amount of HA
absorbed by Caco-2 cells increases as the MW of HA
decreases to 7 × 104, 2 × 104, or 5 × 103 [29]. Kurihara et
al. reported that HA is decomposed into 2–6-membered
polysaccharides by enteric bacteria, and these polysac-
charides are partially absorbed into the body by the
small intestine [30]. Following the decomposition of HA
by enteric bacteria to a low MW form, free polysaccha-
rides are known to migrate into the joints and other tis-
sues. Lactobacillus and Bzfidobacterirn have been
reported as examples of enteric bacteria that play a crit-
ical role in HA absorption [31]. Balogh et al. reported
that 99 mtechnetium-labeled HA (MW, 1 × 106) is accu-
mulated by tissues such as joints after oral administra-
tion in rats and dogs [32]. The pattern of tissue uptake
of radioactivity for 99mtechnetium-labeled HA did not
resemble that for 99mtechnetium-labeled pertechnetate
(PCT), which was used as a control; this implies that
99mtechnetium-labeled HA did not release 99mtechne-
tium in tissues.
These studies clearly suggest that HA is absorbed by
the body; however further research is needed to clarify
the effects of the route of absorption on knee pain relief.
Another mechanism was clarified by Asari et al. in
2010 [33]. This report identified a signaling cascade in
which receptors on intestinal epithelial cells are activated
by oral HA which results in decreased pain. HA (MW,
9 × 105; Hyabest® (J), Kewpie Corporation, Tokyo, Japan)
was administered orally to MRL-lpr/lpr mice, a Th-1-
type autoimmune disease model. Oral HA binds to an
intestinal receptor (Toll-like receptor-4;TLR-4). Cyto-
kine array analysis showed that HA enhanced the pro-
duction of interleukin-10 (IL-10), an anti-inflammatory
cytokine. DNA array analysis of tissue from the large in-
testine showed that HA up-regulates suppressor of cyto-
kine signaling 3 (SOCS3) expression and down-regulates
pleiotrophin expression. These results suggest that the
binding of HA to TLR-4 promotes IL-10 and SOCS3 ex-
pression and suppresses pleiotrophin expression leading
to anti-inflammation of arthritis (Fig. 2).
Clinical trials of oral HA for the treatment of knee
pain
We searched the databases up to October 29, 2015;
PubMed, the Cochrane Library, Scopus, UMIN-CTR,
JDreamIII (in Japanese), and Ichushi Web (in Japanese).
The search words used for all databases contained the
terms; hyaluronan, intake and knee pain. We selected fol-
lowing 13 relevant reports after full text review [31–43].
Many randomized, double-blind, placebo-controlled
trials have demonstrated the effectiveness of dietary HA
in alleviating knee pain since 2008 in the US, EU, and
Asia (Table 1).
In 2008, a dietary supplement containing HA as the
principal ingredient was reported following two clinical
trials. As the supplement contains multiple components,
the potential effects of ingredients other than HA on
knee pain cannot be denied but the effects of the supple-
ment on knee pain were confirmed.
Hatayama et al. [34] treated 24 Japanese patients with
chronic knee pain (HA group, n = 13; placebo group, n
= 11, mean age, 47.5) with an HA mixture at a dose of
1800 mg/day (HA content, 60 mg/day) or placebo for
2 weeks. The HA group displayed a significant improve-
ment in knee pain and discomfort compared with the
placebo group (p < 0.05).
In the US, Kalman et al. [35] treated 20 subjects aged
≥40 years with knee OA (HA group, n = 11; placebo
group, n = 9, mean age, 56.3) with an HA mixture at a
dose of 80 mg/day (HA content, 48 mg/day) or placebo
for 2 months and their outcomes were evaluated using
the index for knee joint pain; the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC),
and the Short Form-36 Acute US Version 2 (SF-36v2) as
a quality of life (QOL) index. [REMARK 4] The
WOMAC score in both groups revealed significant im-
provements in knee pain compared with baseline (p <
0.05) but the physical function and total symptom scores
of the HA group displayed a more drastic improvement
than those of the placebo group. On the SF-36 v2, the
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scores of the HA group were significantly improved ver-
sus baseline (p < 0.05) for bodily pain and the physical
component summary, and the scores were more signifi-
cantly improved in the HA group than in the placebo
group.
In 2009, two clinical trials using highly pure HA (more
than 98 % pure) were reported. These trials revealed that
the effects of HA-containing supplements on knee pain
were attributable to HA.
Iwaso et al. [36] reported that 33 Japanese patients
with knee pain (HA group, n = 16; placebo group, n = 17,
mean age, 58.3) were administered HA at 240 mg/day or
placebo for 8 weeks and outcomes were evaluated using
the Japanese Knee Osteoarthritis Measure (JKOM). The
JKOM score was significantly improved compared with
baseline in both groups (p < 0.01), particularly among 26
patients aged 50–65 years (HA group, n = 13; placebo
group, n = 13). Significant improvements in knee pain
and stiffness were recorded in the HA group compared
with the placebo group (p < 0.05).
Sato et al. [37] reported a study in which 37 Ameri-
cans with knee OA (HA group, n = 20; placebo group, n
= 17, mean age, 70.8) were orally administered 200 mg/
day HA or placebo for 8 weeks with the findings il-
lustrating that the WOMAC score was significantly
improved in both groups versus baseline (p < 0.05),
particularly among the 25 patients with WOMAC
pain scores of more than 10 (HA group, n = 13; pla-
cebo group, n = 12). In addition, the WOMAC total
score and activity of daily living score were signifi-
cantly improved in the HA group compared with the
placebo group (p < 0.05).
In the same year, Möller et al. [38] conducted a retro-
spective cohort study in Spain in which HA was com-
pared with the analgesic drug paracetamol (PCT).
Sixty-nine patients (mean age, N/A) with knee OA and
synovitis were administered an HA mixture at 80 mg/
day (HA content, 48 mg/day) or PCT for 6 months.
Ultrasonography showed that the course of synovitis in
the suprapatellar recess was significantly reduced in the
HA group compared with the PCT group (p < 0.0001),
and the number of severe synovial effusion cases were
significantly reduced in the HA group compared with
the PCT group (p < 0.001).
Fig. 2 Mechanism of improve the arthritis. Oral administration of hyaluronan modulates inflammation by upregulating suppressor of cytokine
signaling-3 expression and down-regulating pleiotrophin expression via Toll-like receptor-4 in intestinal epithelial cells
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Between 2010 and 2015, eight clinical trials were re-
ported indicating that interest in HA intake was becom-
ing more intense in developed nations.
In 2010, Nagaoka et al. [39] reported that 40 Japanese
patients with knee OA (HA group, n = 19; placebo
group, n = 21, mean age, 62.9) were administered an oral
HA mixture at 1800 mg/day (HA content, 60 mg/day)
or placebo for 4 months and the result illustrated that
pain/step-up and step-down function and the aggregate
total symptoms of the Japanese Orthopaedic Association
clinical trials response criteria were significantly im-
proved in the HA group compared with the placebo
group (p < 0.05) indicating relief of knee pain.
In 2012, Yoshimura et al. [40] reported that 29 Japa-
nese athletes (HA group, n = 14; placebo group, n = 15,
mean age, 20.0) were administered an HA mixture at
4800 mg/day (HA content, 72 mg/day) or placebo for
12 weeks. The urine levels of the bone metabolic
markers N-terminal telopeptides of bone-specific type I
collagen were significantly lower in the HA group (p <
0.05). This result indicates that oral HA influences knee
joint health.
Tashiro et al. [41] reported a study in which 38 Japa-
nese patients with knee OA (HA group, n = 18; placebo
group, n = 20, mean age, 69.9) were administered highly
pure HA (more than 97 %) at 200 mg/day or placebo for
12 months. During the trial, the patients were requested
to conduct quadriceps-strengthening exercise daily as
part of the treatment. The result reveals that quality of
life according to the JKOM score was significantly im-
proved in the HA group versus the placebo group (p <
0.05) and this trend was more obvious among patients
aged ≤70 years (n = 21). For these relatively younger pa-
tients in the HA group, the total JKOM score was sig-
nificantly better than that in the placebo group (p <
0.05). Thus, HA intake and quadriceps-strengthening ex-
ercise affectively alleviate knee pain particularly in pa-
tients aged ≤70 years (Fig. 3).
In 2013, Martinez-Puig et al. [42] reported that 50
healthy subjects with joint discomfort (VAS between 10
and 40 mm; HA group, n = 20; placebo group, n = 20,
mean age, 59.6) were administered an HA mixture at
80 mg/day (HA content, 48 mg/day) or placebo for
90 days and outcomes were evaluated using an isokinetic
dynamometer. Maximum peak torque was significantly
greater in the HA group than in the placebo group (p <
0.05). In the HA group, the total knee extension and
mean power of knee extension were also significantly
higher than the values in the placebo group (p < 0.05).
This trial demonstrated that oral HA effectively im-
proves the ability of the knee joint to bend and stretch.
Moriña et al. [43] reported a meta-analysis of two ran-
domized, controlled, double-blind, placebo-controlled
trials involving a total of 148 patients with mild knee
pain (VAS between 30 and 50 mm, aged from 20 to 75).
In the studies, patients were administered an oral HA
mixture at 80 mg/day (HA content, 48 mg/day) or pla-
cebo for 3 months and outcomes were evaluated using
an isokinetic dynamometer. The analysis indicated that
the affected joint displayed greater flexion in the HA
group than in the placebo group (p = 0.039). The result
of ultrasound examination for synovial effusion illus-
trated that synovial effusion was significantly reduced in
the HA group (p = 0.029). An evaluation using a VAS in-
dicated that knee pain was additionally improved in the
HA group compared with the findings in the placebo
group (p = 0.0036).
In 2014, Sánchez et al. [44] reported that 68 patients
with mild knee pain (VAS between 30 and 50 mm; HA
group, n = 34; placebo group, n = 34, mean age, 69.5)
were administered an oral HA mixture at 80 mg/day
(HA content, 48 mg/day) or placebo for 90 days. A sig-
nificant improvement in knee pain according to the VAS
was recorded in the HA group compared with the pla-
cebo group (p = 0.0005). An ultrasound examination in-
dicated that synovial effusion was reduced in the HA
group (p = 0.041). The result using an isokinetic
Fig. 3 Oral hyaluronan improve knee osteoarthritis: a randomized,
double-blind, placebo-controlled trial. Twenty-one subjects (≤70 years
of age) were randomly divided into two groups (hyaluronan group, n
= 11; placebo group, n = 10). Variations in the total Japanese Knee
Osteoarthritis Measure score relative to baseline are shown. □
hyaluronan; ■ placebo. Values are presented as the mean ± SE.
p < 0.05 vs. baseline; #p < 0.05 vs. placebo group
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Table 2 Safety tests of hyaluronan
Test procedures Subjects Route Results References
Randmized, double-blind,
placebo-controlled trial
Human Oral administration, 60 mg/day for 2 weeks No adverse event
related to hyaluronan.
[34]
Human Oral administration, 48 mg/day for 2 months No adverse event
related to hyaluronan.
[35]
Human Oral administration, 240 mg/day for 8 weeks No adverse event
related to hyaluronan.
[36]
Human Oral administration, 200 mg/day for 8 weeks No adverse event
related to hyaluronan.
[37]
Human Oral administration, 60 mg/day for 4 months No adverse event
related to hyaluronan.
[39]
Human Oral administration, 200 mg/day for 12 months No adverse event
related to hyaluronan.
[41]
Human Oral administration, 52 mg/day for 3 months No adverse event
related to hyaluronan.
[42]
Human Oral administration, 52 mg/day for 3 months No adverse event
related to hyaluronan.
[43]
Human Oral administration for 4 weeks (225 mg/day for first




single-dose toxicity study Mouse Oral administration LD50 (mg/kg) > 2400 [48]
Mouse Oral administration LD50 (mg/kg) > 500 [49]
Rat Oral administration LD50 (mg/kg) > 800 [48]
Rat Oral administration LD50 (mg/kg) > 200 [50]
Rabbit Oral administration LD50 (mg/kg) > 1000 [48]
Repeated-dose toxicity study Rat Subcutaneous administration for 13 weeks with 4 weeks
recovery test
NOAEL 50 mg/kg/day [51]
Beagle dog Subcutaneous administration for 13 weeks with 4 weeks
recovery test
NOAEL 10 mg/kg/day [52]
Rat Oral administration for 30 days NOAEL 1500 mg/kg/day [53]
Rat Oral administration for 90 days NOAEL 1333 mg/kg/day [54]
Rat Oral administration for 90 days NOAEL 1000 mg/kg/day [55]
Rat Oral administration 28 days NOAEL 3500 mg/kg/day [56]
Rat Intraperitoneal administration 90 days NOAEL 9 mg/kg/day [57]
Rat Intraperitoneal administration for 3 months NOAEL 60 mg/kg/day [58]
Rat Oral administration for 13 weeks NOAEL 12.5 mg/kg/day [59]
Rat Oral administration for 90 days with 28 days recovery test NOAEL 48 mg/kg/day [60]
Beagle dog Intra-articular administration for 6 months NOAEL 12 mg/kg/day [61]
Reproductive and developmental
toxicity studies
Rat Subcutaneous administration NOAEL 50 mg/kg/day [62–64]
Rat Oral administration NOAEL 670 mg/kg/day [65]
Rat Subcutaneous administration NOAEL 50 mg/kg/day [66–68]












1.00 mg/mL Negative [71]
Mammalian
cultured cell
1000 μg/plate Negative [72]
Micronucleus test Mouse 300 mg/kg Negative [73]
Mouse Intraperitoneal administration, 30 mg/kg Negative [74]
Antigenicity study Mouse, Rat Intraperitoneal administration, 100 μg/個体 Negative [75]
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dynamometer illustrated that muscular strength (peak
torque) was significantly greater among patients in the
HA group than among those in the placebo group (p =
0.0324). Blood tests for RNA expression were conducted
in 20 patients (HA group, n = 10; placebo group, n = 10).
The results demonstrated that the expression of genes
related to glycosaminoglycan metabolism and extracellu-
lar matrix dynamics differed between the HA and pla-
cebo groups. It was concluded that differences in gene
expression explained the improvements in knee pain
and muscular strength in the HA group.
In 2015, Nelson et al. [45] treated 40 patients with
knee OA (VAS > 50 mm; HA group, n = 21; placebo
group, n = 19, mean age, 61.0) with an oral HA mixture
at 80 mg/day (HA content, 56 mg/day) or placebo for
3 months. Significant improvements in the VAS,
WOMAC total score, and WOMAC pain score were ob-
served in the HA group compared with the placebo
group (p < 0.05). An analysis of serum and synovial fluid
illustrated that inflammatory cytokine levels were signifi-
cantly increased in the placebo group (p < 0.05) and sig-
nificantly decreased in the HA group (p < 0.05).
Regarding bradykinin, which related to inflammation
and pain, and leptin, which is related to OA caused by
obesity, the levels of both substances were significantly
lower in the HA group than in the placebo group (p <
0.05). Ten patients in each group drank large amounts
of water to examine the turnover of HA in synovial fluid.
The turnover rate was significantly decreased in the HA
group compared with that in the placebo group (p =
0.046). Consequently, this report demonstrated that the
oral intake of HA is useful for treating obese patients
with OA.
In 2015, Jensen et al. [46] conducted a study in which
72 patients with knee OA (HA group, n = 37; placebo
group, n = 35, mean age, 47.2) were administered a li-
quid HA mixture or placebo for 4 weeks. For the first
2 weeks, the HA mixture was given at 45 mL/day (HA
content, 225 mg/day) and it was given at 30 mL/day
(HA content, 150 mg/day) for the next 2 weeks. After
2 weeks of intake, knee pain as evaluated using a VAS
was significantly improved in the HA group compared
to baseline (p < 0.05). On the contrary, no improvement
in knee pain was recorded in the placebo group. Thus,
oral HA can relieve knee pain.
Among all the studies on clinical trials from 2008 to
2015, seven studies involved the treatment of the
symptoms associated with synovitis, mainly pain [33–37,
39, 41, 46]; four involved measures taken to relieve syn-
ovial effusion or inflammation [38, 43–45]; and three in-
volved measures taken to improve knee muscular
strength [42–44].
The studies that used a mixture containing HA and
other components could not rule out the possibility that
the other components had effects on knee pain. How-
ever, studies that used highly pure HA (more than 97 %)
also reported a beneficial effect on knee pain. Thus, oral
HA can effectively improve knee pain.
It is apparent that there were slightly more female sub-
jects than males investigated in the above-mentioned
clinical studies (mean ratio: males 43 %, females 57 %).
However, each study involved the same gender ratio for
HA and placebo groups. In general, the number of fe-
male OA patients was larger than the number of males.
This is probably because females have lesser muscles
than males and therefore, the burden on the knee in-
creases. It has been reported that HA is regulated by
ovarian steroids [47]; however, it is not yet clear whether
the oral intake of HA influences hormonal balance. This
needs further research.
HA intake differs among the respective studies, such
as 48–240 mg/day for 2 weeks–12 months. Thus, further
research is needed to clarify the minimal effective dose
and the minimum intake period of HA.
Safety of HA
Chicken comb, which contains highly concentrated HA
has long been consumed in Germany, France, and
China. In Japan, HA dietary supplements have been
available since 1992. HA is approved as a healthy raw
material of new resource food in China, as a food addi-
tive and healthy functional food in Korea, and as a food
additive in Japan. In addition, HA is sold globally in
countries such as the US, Canada, Italy, and Belgium
and no adverse event caused by HA has been reported.
Several safety studies of HA have been conducted
(Table 2). No toxicity was observed in single-dose tox-
icity studies [48–50], repeated-dose toxicity studies [51–
61], reproductive and developmental toxicity studies
[62–69], mutagenicity tests [70–74], and antigenicity
studies [75, 76]. It is reported that exogenous HA such
us that administered orally is not harmful to human can-
cer cells [77]. A 12 month clinical study identified no ad-
verse event attributable to HA [41]. Orally administrated
Table 2 Safety tests of hyaluronan (Continued)
Guinea pig Negative
Rabbit Intramuscularl administration, 30 mg/kg Negative [76]
Influence on cancer cell Mouse, cell Oral administration, 200 mg/day No influence on cancer
cell
[77]
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HA is used by body tissues and approximately 90 % of
exogenous HA is metabolized and released in expiration
and urine; thus, the polysaccharide does not accumulate
at excessive levels in the body [78]. There were no ad-
verse events attributable to HA in any of the aforemen-
tioned clinical trials [34–44]. Based on these factors, HA
can be considered as a safe food material.
Conclusion
The population is aging rapidly around the world. In
addition to medical treatment, self-medication is more
commonly practiced to reduce patient burden and en-
hance QOL. HA is a safe raw material and the efficacy
of oral HA in relieving knee pain was demonstrated in
several clinical trials. HA as a dietary supplement ex-
hibits mild efficacy and no side effects. By utilizing these
characteristics, HA dietary supplements provide at least
some possibility for the treatment and prevention of ser-
ious conditions in patients with OA exhibiting mild knee
pain. This review may improve the understanding of HA
dietary supplements and it is expected that HA will
emerge as a modality for treating knee pain that can be
safely used by patients.
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